Fezolinetant will be listed at the top of the non-hormonal treatment options in the Menopause & HRT formulary in both EMIS and S1, reflecting its status as the preferred non-hormonal choice.

The LNG-IUD expiry date check will be added to the initial consultation and review pages of the menopause template in both EMIS and S1, prompting clinicians to ensure appropriate endometrial protection is prescribed where needed.